Semaglutide + BIMAGRUMAB for obesity

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 14 Nov 2022: Trial registered, NCT05616013
  2. 16 Nov 2022: Trial started, NCT05616013

The trials

NCT05616013: Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese

State
Completed
Phase
Phase 2
People
507 taking part
Started
16 Nov 2022
Primary completion
16 May 2024
Arms
10 mg/kg Bimagrumab + 1.0 mg Semaglutide, 10 mg/kg Bimagrumab + 2.4 mg Semaglutide, 30 mg/kg Bimagrumab + 1.0 mg Semaglutide, 30 mg/kg Bimagrumab + 2.4 mg Semaglutide
Results
Posted on the registry
  1. 14 Nov 2022: Trial registered
  2. 16 Nov 2022: Trial started
  3. 14 Jun 2025: Trial completed
  4. 18 Jul 2025: Trial results posted

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.